Tag: MONOGRAPH

  • MitoQ

    Mitochondria-targeted ubiquinone-derived antioxidant conjugated to a triphenylphosphonium cation

    A synthetic coenzyme Q10 analog covalently linked to a lipophilic triphenylphosphonium moiety that drives selective mitochondrial accumulation, enabling targeted quenching of reactive oxygen species at the inner mitochondrial membrane with demonstrated vascular, hepatoprotective, and anti-inflammatory activity in human clinical studies.

    Abstract

    Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CP2

    Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

    A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.

    Abstract

    CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Fluvoxamine

    Selective serotonin reuptake inhibitor with high-affinity sigma-1 receptor agonism

    A 2-aminoethyl oxime ether SSRI developed at Kali-Duphar as an antidepressant and anti-obsessional agent, distinguished from other serotonin reuptake inhibitors by potent sigma-1 receptor agonism and downstream anti-inflammatory, cytoprotective, and endoplasmic reticulum chaperone activity.

    Abstract

    Fluvoxamine, the (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, is a selective serotonin reuptake inhibitor (SSRI) of the 2-aminoethyl oxime ether structural class, first introduced in Switzerland in 1983 as Floxyfral and approved by the United States Food and Drug Administration in December 1994 for the treatment of obsessive-compulsive disorder (OCD). It is marketed in approximately 80 countries under the trade names Luvox, Fevarin, Faverin, Floxyfral, and Dumyrox for indications including OCD, social anxiety disorder (SAD), and major depressive disorder (MDD), with the extended-release formulation (Luvox CR) approved in the United States in 2008 for both OCD and SAD. Fluvoxamine is pharmacologically distinguished from the other marketed SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) by its potent agonism at the sigma-1 receptor, a ligand-regulated endoplasmic reticulum chaperone protein, with a binding affinity (Ki approximately 36 nM) that is the highest of any clinically used SSRI and approximately 10-fold greater than that of sertraline, the next most potent sigma-1 ligand in the class [1, 2]. The sigma-1 receptor activity, formally characterized by Narita et al. (1996) and subsequently extended by multiple laboratory groups in rodent models and by Hashimoto and colleagues in translational studies, drives a pharmacological profile that extends substantially beyond serotonin reuptake inhibition: activation of the sigma-1 receptor chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM) modulates the inositol 1,4,5-trisphosphate receptor (IP3R), stabilizes the IRE1-BiP complex under endoplasmic reticulum stress, suppresses NLRP3 inflammasome and NF-kappaB-driven proinflammatory cytokine release, and potentiates nerve growth factor-induced neurite outgrowth in neuronal cell models [3, 4, 5]. Pharmacokinetics in humans are characterized by near-complete gastrointestinal absorption, approximately 53 percent oral bioavailability due to first-pass hepatic metabolism, a plasma elimination half-life of 12 to 15 hours after single doses (extended at steady state owing to nonlinear pharmacokinetics from autoinhibition of CYP1A2 and CYP2C19), and oxidative demethylation through CYP2D6 and CYP1A2 followed by glucuronide conjugation and renal excretion [7, 8]. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9, producing clinically significant drug-drug interactions with theophylline, tizanidine, alosetron, clozapine, warfarin, and ramelteon, among others [9]. The compound is well tolerated at registered doses; the principal adverse events are nausea (up to 40 percent), somnolence, insomnia, headache, and asthenia, with serotonin syndrome as a rare but serious risk in combination with other serotonergic agents or monoamine oxidase inhibitors. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dihydro-NMN

    Reduced pyridine nucleotide and potent NAD+ precursor of the dihydronicotinamide mononucleotide class

    A reduced-form nicotinamide mononucleotide that bypasses canonical salvage pathway enzymes to elevate cellular NAD+ and NADH more rapidly and to a greater extent than its oxidized counterpart NMN, with emerging preclinical evidence in renal cytoprotection, metabolic reprogramming, and anti-proliferative activity.

    Abstract

    Dihydronicotinamide mononucleotide (NMNH), also designated reduced nicotinamide mononucleotide or dihydro-NMN, is the 1,4-dihydropyridine analog of beta-nicotinamide mononucleotide (NMN). The compound differs from NMN by a single additional hydrogen at the C-4 position of the nicotinamide ring, converting the aromatic pyridinium to a non-aromatic 1,4-dihydropyridine and conferring distinct biochemical, pharmacokinetic, and pharmacological properties. NMNH was first characterized as a potent nicotinamide adenine dinucleotide (NAD+) precursor in mammalian systems in two independent 2021 reports: Zapata-Perez et al. in The FASEB Journal demonstrated that NMNH increases NAD+ levels to a substantially greater extent and faster than NMN or nicotinamide riboside (NR) across multiple tissues in mice, while Liu et al. in the Journal of Proteome Research showed that NMNH potently enhances NAD+ and NADH, suppresses glycolysis and the tricarboxylic acid cycle, induces reductive stress, and inhibits cell growth in hepatocellular carcinoma cells. The metabolic pathway of NMNH is mechanistically distinct from that of NMN: NMNH is converted directly to NADH by nicotinamide mononucleotide adenylyltransferase (NMNAT) without requiring nicotinamide phosphoribosyltransferase (NAMPT) or nicotinamide riboside kinase (NRK), the two rate-limiting enzymes of the canonical salvage and Preiss-Handler pathways. The resulting NADH is then oxidized to NAD+ by cellular oxidoreductases, producing a net elevation of both reduced and oxidized pyridine dinucleotide pools. In vivo, intraperitoneal administration of NMNH to mice elevates hepatic NAD+ approximately five-fold and renal NAD+ approximately two-fold, with significant increases also observed in brain, skeletal muscle, brown adipose tissue, and heart, tissues in which equivalent doses of NMN produce no statistically significant NAD+ elevation. The Zapata-Perez et al. study additionally demonstrated that NMNH protects conditionally immortalized proximal tubular epithelial cells against hypoxia and reoxygenation injury, reducing expression of the kidney injury biomarker Kim-1 and the mitochondrial dysfunction marker Tfam, establishing a preclinical basis for renal cytoprotection. The Liu et al. metabolomic analysis revealed that NMNH-treated cells exhibit marked suppression of glycolytic intermediates (glucose-6-phosphate, fructose-1,6-bisphosphate, phosphoenolpyruvate, pyruvate) and tricarboxylic acid cycle intermediates (citrate, alpha-ketoglutarate, succinate, fumarate, malate), accompanied by cell cycle arrest and growth inhibition. The compound induces cellular reductive stress through elevation of the NADH/NAD+ ratio, which paradoxically increases reactive oxygen species (ROS) production, linking the reductive stress phenotype to the anti-proliferative activity. NMNH is prepared by chemical reduction of NMN with thiourea dioxide in alkaline aqueous solution or by enzymatic cleavage of NADH with NADH pyrophosphatase (NudC). The compound is supplied as the disodium salt (CAS 108347-85-9) and is commercially available from multiple research chemical suppliers. No regulatory approval exists for NMNH in any jurisdiction; the compound is sold as a dietary supplement or research reagent. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SRT2104

    Selective small-molecule allosteric activator of NAD-dependent protein deacetylase sirtuin 1 (SIRT1)

    A second-generation imidazothiazole-scaffold sirtuin 1 activator developed by Sirtris Pharmaceuticals and advanced through multiple Phase 2 clinical programs by GlaxoSmithKline, distinguished from first-generation sirtuin-activating compounds by high target selectivity and favorable oral pharmacokinetics.

    Abstract

    SRT2104 (GSK2245840) is a synthetic, orally bioavailable, small-molecule allosteric activator of the NAD-dependent protein deacetylase sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1), developed at Sirtris Pharmaceuticals and subsequently advanced into clinical trials by GlaxoSmithKline following the 2008 acquisition of Sirtris for approximately 720 million United States dollars. The compound is a second-generation sirtuin-activating compound (STAC) built on an optimized imidazo[2,1-b]thiazole scaffold and is reported to activate SIRT1 deacetylase activity approximately 1000-fold more potently than the natural polyphenol resveratrol in fluorophore-tagged peptide substrate assays, with minimal activity against a panel of more than 180 non-SIRT1 targets including kinases, G-protein-coupled receptors, nuclear receptors, ion channels, enzymes, and transporters [1, 2]. The allosteric mechanism involves binding to the N-terminal domain of SIRT1, lowering the Michaelis constant (Km) for the acetylated protein substrate without competing with either the NAD cofactor or the substrate acetyl-lysine site [3]. Downstream consequences of SIRT1 activation by SRT2104 include deacetylation and functional modulation of the transcription factor p53, the RelA/p65 subunit of nuclear factor kappa B (NF-kB), forkhead box protein O3 (FOXO3), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), and signal transducer and activator of transcription 3 (STAT3), producing composite anti-inflammatory, metabolic, and cytoprotective effects that have been characterized across a broad range of preclinical disease models [4, 5].

    The variable and non-dose-proportional pharmacokinetic profile has been identified as a principal limitation of the compound for clinical development in its current oral formulation. SRT2104 is poorly soluble in water and is formulated as a lipid-based oral capsule to improve bioavailability.

    Clinical evaluation has spanned at least seven registered clinical trials across multiple indications. A separate cardiometabolic study in type 2 diabetic subjects reported trends toward improved endothelial function and arterial stiffness [9]. In a human endotoxemia model, SRT2104 pretreatment significantly reduced lipopolysaccharide-induced cytokine release (interleukin-6, interleukin-8) and coagulation activation, representing the first human demonstration of anti-inflammatory and anticoagulant activity consistent with pharmacological SIRT1 activation [12].

    Preclinical pharmacology is extensive. The Mercken et al. (2014) study at the National Institute on Aging demonstrated that SRT2104 extends both mean and maximum lifespan of male mice fed a standard diet by 9.7 percent and 4.9 percent respectively, with preserved bone mineral density, muscle mass, motor coordination, and insulin sensitivity [13]. The Jiang et al. (2014) study demonstrated blood-brain barrier penetration, attenuation of brain atrophy, improvement of motor function, and extension of median lifespan by approximately 16 percent in N171-82Q Huntington disease model mice [14]. Additional preclinical evidence spans emphysema, sepsis, neonatal white matter injury, microglia polarization, dendritic outgrowth, and auditory cell senescence. GlaxoSmithKline discontinued active clinical development of SRT2104 following the 2013 closure of the Sirtris unit, though the compound remains widely used as a reference SIRT1 activator in academic and preclinical research. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • EPI-743

    Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone

    A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augmenter of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.

    Abstract

    EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all of BioElectron’s assets, including the vatiquinone program, in October 2019 for approximately $210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population (p = 0.14), though statistically significant effects were observed on the pre-specified upright stability subscale (p = 0.021) and in the per-protocol population (p < 0.05). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 17-alpha-Estradiol

    Non-feminizing endogenous estradiol stereoisomer with 5-alpha-reductase inhibitory activity and lifespan-extending properties

    A naturally occurring 17-alpha-epimer of estradiol with approximately 100-fold reduced classical estrogen receptor affinity, topical registration as alfatradiol for androgenetic alopecia, and reproducible male-specific lifespan extension in the NIA Interventions Testing Program, mediated through estrogen receptor alpha signaling in the hypothalamus and liver.

    Abstract

    17-alpha-Estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; alfatradiol; molecular formula C18H24O2; molecular weight 272.39 g/mol) is the 17-alpha-stereoisomer of the principal mammalian estrogen 17-beta-estradiol, distinguished solely by the axial (alpha) orientation of the hydroxyl group at carbon 17 of the steroid D-ring. The compound occurs endogenously at low concentrations in mammalian brain and peripheral tissues and has been characterized since the 1950s as a weak estrogen with approximately 100-fold lower binding affinity for the classical nuclear estrogen receptors ER-alpha and ER-beta relative to the 17-beta-epimer [1, 2]. Despite this reduced receptor engagement, 17-alpha-estradiol retains potent estrogen receptor-independent antioxidant activity equivalent to 17-beta-estradiol in lipid peroxidation assays and neuroprotection models [3, 4], inhibits 5-alpha-reductase and aromatase in skin and hair follicle tissue (the basis for its topical registration as alfatradiol in several European jurisdictions for androgenetic alopecia) [5, 6], and has emerged as one of the most robustly validated lifespan-extending compounds in the National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse longevity screening platform.

    The ITP demonstrated that dietary 17-alpha-estradiol at 14.4 parts per million (approximately 2 mg/kg/day mouse-equivalent) extended median lifespan by approximately 19 percent in male UM-HET3 mice when initiated at 16 months of age and by approximately 11 percent when initiated at 20 months, with no lifespan extension observed in female mice at any initiation age [7, 8, 9]. The male specificity of the lifespan effect has been replicated across three independent ITP sites (the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center) and is among the largest and most reproducible lifespan extensions reported in the ITP, comparable in magnitude to acarbose and exceeded only by rapamycin. The sex-specific pattern has driven substantial mechanistic investigation. Stout et al. (2017) demonstrated that 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization, with treated males showing reduced fasting glucose, reduced fasting insulin, reduced glycosylated hemoglobin, reduced visceral adiposity, reduced circulating and adipose tissue pro-inflammatory cytokines, and increased AMP-activated protein kinase activity in visceral adipose tissue [10]. Steyn et al. (2018) established that 17-alpha-estradiol acts through hypothalamic pro-opiomelanocortin (POMC) expressing neurons to reduce feeding behavior, with near-complete loss of the anorectic response in POMC-neuron-ablated mice [11]. Mann et al. (2020) demonstrated through liver-specific and global ER-alpha knockout models that the metabolic health benefits of 17-alpha-estradiol (reductions in fasting insulin, HbA1c, glucose intolerance, and visceral adiposity) are mediated through estrogen receptor alpha, resolving prior uncertainty about whether a non-classical receptor was responsible [12]. Garratt et al. (2017, 2018) reported that males, but not females, metabolize 17-alpha-estradiol into one or more estriol derivatives, and that the sex-specific beneficial effects may depend on a downstream metabolite rather than on the parent compound [13, 14].

    The compound has limited human clinical data. Topical formulations (alfatradiol 0.025 percent solution, marketed as Ell-Cranell alpha) are registered in Germany, Austria, and several other European jurisdictions for androgenetic alopecia in men and women, with demonstrated stabilization of hair loss through local 5-alpha-reductase inhibition and aromatase induction [5, 6]. No clinical trials of oral 17-alpha-estradiol for longevity, metabolic, or neuroprotective endpoints have been completed or registered in humans as of the monograph revision date.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Honokiol

    Biphenyl neolignan polyphenol with pleiotropic GABAA receptor positive allosteric modulation, SIRT3 activation, and multi-pathway anti-inflammatory and antineoplastic activity

    A naturally occurring biphenolic neolignan isolated from Magnolia officinalis bark, distinguished by positive allosteric modulation of GABAA receptors, direct activation of mitochondrial sirtuin-3, and broad-spectrum preclinical activity across oncology, neuroprotection, anxiolysis, and inflammation.

    Abstract

    Honokiol (3′,5-di-2-propenyl-1,1′-biphenyl-2,4′-diol) is a biphenyl neolignan polyphenol isolated principally from the bark, seed cones, and leaves of Magnolia officinalis and related species of the genus Magnolia, a botanical source with documented use in traditional Chinese, Japanese, and Korean medicine for over two thousand years. The compound has attracted substantial modern pharmacological interest owing to a pleiotropic mechanism profile that includes positive allosteric modulation of both synaptic and extrasynaptic GABAA receptors at a site distinct from the benzodiazepine binding site; direct activation of the mitochondrial deacetylase sirtuin-3 (SIRT3) with consequent enhancement of mitochondrial respiration, ATP production, and antioxidant defense; agonism at peroxisome proliferator-activated receptor gamma (PPARgamma); inhibition of nuclear factor kappa-B (NF-kB) and signal transducer and activator of transcription 3 (STAT3) signaling; modulation of the PI3K/Akt/mTOR axis; and disruption of the PSD95-nNOS protein-protein interaction at glutamatergic synapses. The preclinical pharmacology of honokiol spans four principal domains. In oncology, honokiol inhibits proliferation, induces apoptosis through both intrinsic and extrinsic pathways, suppresses angiogenesis, and reduces metastatic potential in cell-line and xenograft models of breast, colon, prostate, lung, glioblastoma, and hematological malignancies, with demonstrated activity against NF-kB, STAT3, EGFR, and survivin signaling. In neuroprotection, honokiol preserves neuronal viability against amyloid-beta toxicity, glutamate excitotoxicity, and oxidative insult through SIRT3-dependent mitochondrial stabilization, reduction of reactive oxygen species, suppression of intracellular calcium elevation, and inhibition of caspase-3 activation. In anxiolysis and sedation, honokiol potentiates GABAergic neurotransmission at concentrations below those required for overt sedation, producing anxiolytic-like behavioral effects in rodent models without the tolerance, dependence, and amnesia liabilities associated with classical benzodiazepines. In inflammation, honokiol suppresses NF-kB-driven proinflammatory cytokine release, reduces glial activation in cerebral ischemia-reperfusion models, and attenuates inflammatory markers in models of sepsis, diabetic nephropathy, and postoperative cognitive decline. The compound readily crosses the blood-brain barrier, a property that distinguishes it from many polyphenols of comparable molecular weight and that supports the observed central nervous system effects. The principal circulating species after oral administration is the monoglucuronide conjugate rather than free honokiol. Clinical evidence in humans is limited. A Phase I trial of liposomal honokiol in patients with relapsed or progressed malignant glioma reported safety, tolerability, and preliminary survival benefit with a dose-response relationship. Phase II trials of liposomal honokiol are ongoing in China. No regulatory authority has approved honokiol as a pharmaceutical agent. The compound is available as a dietary supplement ingredient in several jurisdictions and as a research-grade chemical from multiple suppliers. Investigators should obtain analytical confirmation of identity, purity, and honokiol-to-magnolol ratio on every lot. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Acarbose

    Pseudotetrasaccharide alpha-glucosidase inhibitor with pancreatic alpha-amylase inhibitory activity

    A microbially derived pseudotetrasaccharide developed at Bayer AG as a competitive intestinal alpha-glucosidase and pancreatic alpha-amylase inhibitor for postprandial glucose control in type 2 diabetes mellitus, with emerging preclinical evidence for lifespan extension, gut microbiome modulation, and cardiovascular risk reduction.

    Abstract

    Acarbose is a pseudotetrasaccharide alpha-glucosidase inhibitor isolated from fermentation cultures of the actinobacterium Actinoplanes utahensis and subsequently produced at industrial scale by Actinoplanes sp. SE50/110. The compound competitively and reversibly inhibits the brush border alpha-glucosidases (maltase-glucoamylase, sucrase-isomaltase) of the small intestinal epithelium and, at higher concentrations, pancreatic alpha-amylase, thereby delaying the hydrolysis of complex carbohydrates and oligosaccharides to absorbable monosaccharides and producing a dose-dependent reduction in postprandial glycemic excursion without direct stimulation of insulin secretion [1, 2]. Acarbose received its first regulatory approval in Germany in 1990 and was approved by the United States Food and Drug Administration in 1995 under the trade name Precose; it is marketed in over 100 countries worldwide as Glucobay (Bayer) and under multiple generic names. The compound is one of the most widely prescribed antidiabetic agents in East Asia, where postprandial hyperglycemia contributes disproportionately to overall glycemic burden in carbohydrate-rich dietary patterns. The pharmacokinetic profile of acarbose is dominated by its topical mechanism of action within the gastrointestinal lumen. Less than 2 percent of an oral dose is absorbed as intact drug; the remainder is degraded by intestinal bacteria and digestive enzymes in the distal small intestine and colon, producing at least 13 metabolites, of which one (4-methylpyrogallol and its conjugates) accounts for the majority of systemically absorbed radioactivity [3, 4]. Systemic exposure is therefore minimal, and the pharmacodynamic effect is determined by intraluminal drug concentration relative to the enzyme targets rather than by plasma pharmacokinetics. The compound is not metabolized by hepatic cytochrome P450 enzymes and has negligible renal clearance of intact drug. Clinical evidence for acarbose in type 2 diabetes mellitus is extensive. The UKPDS 44 substudy confirmed sustained glycemic efficacy over 3 years as add-on therapy to sulfonylurea or metformin [7]. The STOP-NIDDM trial (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus) in 1368 subjects with impaired glucose tolerance demonstrated a 25 percent relative risk reduction in progression to type 2 diabetes and a 49 percent relative risk reduction in cardiovascular events over 3.3 years of treatment, though the cardiovascular endpoint was secondary and based on a small number of events [8, 9]. The larger ACE trial (Acarbose Cardiovascular Evaluation) in 6522 Chinese patients with coronary heart disease and impaired glucose tolerance found no reduction in major adverse cardiovascular events over 5 years of follow-up but confirmed an 18 percent relative risk reduction in incident diabetes [10]. Beyond the established antidiabetic indication, acarbose has attracted substantial recent interest as a longevity intervention. The National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse study, demonstrated that acarbose at 1000 ppm in chow extended median lifespan by approximately 22 percent in males and 5 percent in females, with corresponding increases in maximum lifespan [11, 12]. The sex-differential effect parallels the male-preferential lifespan extension observed with 17-alpha-estradiol and nordihydroguaiaretic acid in the same program. Mechanistic investigations have linked the longevity effect to increased delivery of undigested starch to the colonic microbiome, resulting in elevated production of short-chain fatty acids (butyrate, propionate, acetate), shifts in microbial community composition toward Bacteroidetes-dominant profiles, and reductions in circulating insulin-like growth factor 1 (IGF-1) and fasting insulin [13, 14]. Combination of acarbose with rapamycin in the ITP produced additive lifespan extension (median lifespan increases of 28 percent in females and 34 percent in males when initiated at 9 months of age), supporting the hypothesis that the two compounds operate through complementary pathways [15]. Rare hepatotoxicity, presenting as asymptomatic transaminase elevation or, in isolated cases, clinically apparent hepatocellular injury, has been reported in postmarketing surveillance and is generally reversible upon discontinuation [17]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • LM22A-4

    Small-molecule TrkB partial agonist and BDNF loop-domain mimetic

    A synthetic tris(hydroxyethyl) benzenetricarboxamide identified by in silico pharmacophore screening as a sub-nanomolar partial agonist of the TrkB neurotrophin receptor, distinguished by neuroprotective efficacy comparable to BDNF in rodent models of Huntington disease, Rett syndrome, traumatic brain injury, and demyelinating injury, with administration predominantly via the intranasal route owing to limited systemic blood-brain barrier penetration.

    Abstract

    LM22A-4, a synthetic 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide of molecular weight 339.34 g/mol, is a small-molecule partial agonist of tropomyosin receptor kinase B (TrkB) originally identified in 2010 by Massa, Yang, Bhatt, and Longo through in silico pharmacophore screening of commercial chemical libraries against a model of the loop II domain of brain-derived neurotrophic factor (BDNF) [1]. The compound activates TrkB-dependent signaling cascades (phospho-TrkB, phospho-Akt, phospho-ERK1/2) in hippocampal and striatal neurons with a functional EC50 of 200 to 500 picomolar for TrkB activation and an IC50 of 47 nanomolar for competitive displacement of BDNF from the TrkB extracellular domain, producing neuronal survival at 80 to 90 percent of maximal BDNF efficacy in fetal hippocampal neuron assays [1]. The compound is approximately 98 percent smaller than the 27 kDa BDNF homodimer, is freely water-soluble, and is stable in aqueous solution at neutral pH, properties that make it operationally attractive as a research tool for investigating TrkB-dependent neurotrophic signaling in vitro and in vivo. A substantial preclinical literature, principally from the laboratories of Frank Longo and Stephen Massa at Stanford University and the University of California San Francisco, has demonstrated that LM22A-4 prevents neuronal degeneration with efficacy comparable to BDNF in multiple in vitro disease models, including amyloid-beta-induced hippocampal neuron death, MPP+-induced dopaminergic cell death (a Parkinson disease model), and quinolinic acid-induced striatal neuron death (a Huntington disease model) [1]. In vivo, LM22A-4 administered intranasally or by combined intraperitoneal and intranasal routes activates TrkB signaling in mouse hippocampus and striatum and produces functional benefit in rodent models of Huntington disease (R6/2 and BACHD transgenic mice) [2], Rett syndrome (MeCP2 mutant mice) [3, 4], pediatric and adult traumatic brain injury [5, 6], spinal cord injury [7], ischemic stroke [8], demyelinating injury (cuprizone model) [9], and nonarteritic anterior ischemic optic neuropathy [10]. The Huntington disease work by Simmons et al. (2013) demonstrated correction of striatal TrkB signaling deficits, reduction of intranuclear huntingtin aggregates, preservation of medium spiny neuron dendritic spine density, and improvement of motor function across both acute (R6/2) and chronic (BACHD) transgenic models at brain concentrations exceeding the in vitro neuroprotective dose [2]. The Rett syndrome work demonstrated acute reversal of spontaneous apneas and respiratory dysregulation in MeCP2-null and heterozygous mice, with 4-week treatment restoring wild-type breathing frequency and TrkB phosphorylation in medullary and pontine respiratory nuclei [3, 4]. A critical pharmacological limitation is poor blood-brain barrier penetration following systemic administration, which has necessitated intranasal delivery for central nervous system applications in essentially all published in vivo studies [1, 2]. The intranasal route bypasses the blood-brain barrier through olfactory and trigeminal nerve pathways, achieving cerebrospinal fluid and brain parenchymal concentrations sufficient for TrkB activation, but poses translational challenges for clinical development. A second limitation, identified by Bai et al. (2010) and extended by Todd et al. (2014) and subsequent investigations, is mechanistic complexity: multiplex quantitative assays suggest that LM22A-4 may not activate TrkB through direct orthosteric agonism but rather through indirect transactivation mediated by an unidentified G-protein coupled receptor and Src-family kinase (most likely Fyn) signaling [11, 12]. Despite this mechanistic debate, TrkB-dependence of the in vivo effects has been confirmed through conditional oligodendroglial TrkB deletion studies [9], and the functional neuroprotective and neuroregenerative outcomes are reproducible across laboratories and disease models. The compound has not entered human clinical trials as of the most recent monograph revision. It is supplied by multiple research chemical vendors at greater than 98 percent purity and is used exclusively as a research tool. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.